Vertaling van "product contains " (Nederlands → Frans) :

TERMINOLOGIE

container voor bloedverwerkend autotransfusiesysteem
conteneur pour système d’autotransfusion et traitement de sang

container voor besmet afval
réceptacle à déchets contaminés

product dat baclofen bevat
produit contenant du baclofène

product dat basiliximab bevat
produit contenant du basiliximab

product dat balsalazide bevat
produit contenant du balsalazide

product dat enkel auranofine in orale vorm bevat
produit contenant seulement de l'auranofine sous forme orale

product dat auranofine in orale vorm bevat
produit contenant de l'auranofine sous forme orale

product dat aescine bevat
produit contenant de l'aescine

product dat auranofine bevat
produit contenant de l'auranofine

product dat bacitracine bevat
produit contenant de la bacitracine

IN-CONTEXT TRANSLATIONS

A European regulation that has entered into force on 1 July 2004 stipulates that, in order to inform the consumer of possible health risks, the labelling of beverages that contain caffeine in a proportion in excess of 150 mg/l should contain the mention “high caffeine content” followed by the caffeine content expressed in mg/100 ml in the same field of vision as the name under which the product is sold (Directive 2002/67/EC).
Enfin, une réglementation européenne, entrée en vigueur au 1er juillet 2004, stipule que l’étiquetage de boissons contenant plus de 150 mg de caféine par litre doit comporter la mention « teneur élevée en caféine » et la mention de sa quantité (en mg/100 ml) dans le même champ de vision du produit afin d’avertir le consommateur des risques possibles pour la santé (Directive 2002/67/CE).

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

In de 'Code of Practice for the reduction of 3-monochloropropane-1,2-diol (3-MCPD) during the production of acid-hydrolysed vegetable proteins (acid-HVPs) and products that contain acid-HVPs' (in het Engels, Codex Alimentarius, CAC/RCP 64-2008) kunt u preventie- en reductiestrategieën vinden.
Vous trouverez des stratégies de prévention et de réduction dans le « Code d’usages pour la réduction des teneurs en 3-Monochloropropane-1,2diol (3-MCPD) lors de la production de Protéines Végétales Hydrolysées obtenues par voie Acide (PVHA) et de produits contenant ce type de protéines » (Codex Alimentarius, CAC/RCP 64-2008).

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

Als de vloeistof van uiterlijk veranderd is of als de container beschadigd is, moet het product worden weggegooid.
En cas de modification de l’aspect visuel du produit ou d’endommagement du flacon, le produit doit être jeté.

Na dilutie moet het product visueel worden geïnspecteerd om na te gaan of het helder en kleurloos is en nagenoeg geen partikels bevat en of de container niet beschadigd is.
Après dilution, inspecter visuellement le produit pour s’assurer qu’il est limpide, incolore, pratiquement exempt de particules et que le flacon n’est pas endommagé.

De termen en voorwaarden opgenomen in het register op de website van de Europese Commissie vermelden “health claims should only be made for the nutrient, substance, food or food category for which they have been authorised, and not for the food product that contains them”.
Les termes et conditions repris sur le registre du site de la Commission européenne mentionnent que “health claims should only be made for the nutrient, substance, food or food category for which they have been authorised, and not for the food product that contains them”.

At a time of converging trends, which include rising global demand for medicines but also increasing cost-containment pressures, the new leadership team appointed in January 2010 has established priorities to deliver innovation, growth and productivity consistent with the Group’s aspiration to be the world’s most successful and respected healthcare company.
Au moment où se produit une convergence des tendances, notamment une hausse de la demande de médicaments dans le monde entier mais aussi une pression croissante pour contenir les coûts, la nouvelle équipe dirigeante mise en place en janvier 2010 a défini ses priorités afin de promouvoir l’innovation, la croissance et la productivité qui permettront de répondre à l’aspiration du Groupe à être l'entreprise des soins de santé la plus performante et la plus respectée au monde.

3. REFERENTIES BfR Opinion No 041/2010 (2010) Health risks of nitric acid containing cleaning products.
3. REFERENCES BfR Opinion No 041/2010 (2010) Health risks of nitric acid containing cleaning products.

Each 250 ml bottle of this product contains the following ingredients (the following list is restricted to the ingredients that can cause problems in terms of food safety): 80 mg caffeine (or 320 mg/litre), 1 000 mg taurine (4 000 mg/litre), 600 mg glucuronolactone (2 400 mg/litre), 5 µg vitamin B12, 5 µg vitamin B6, 5 mg vitamin B5, 1.5 mg vitamin B2 and 20.5 mg vitamin B3.
Celle-ci contient, par flacon de 250 ml, les composants suivants (liste limitée aux substances pouvant poser problème en termes de sécurité alimentaire): 80 mg de caféine (soit 320 mg/litre), 1.000 mg de taurine (4.000 mg/litre), 600 mg de D-glucuronolactone (2.400 mg/litre), 5 µg de vitamine B12, 5 mg de vitamine B6, 5 mg de vitamine B5, 1,5 mg de vitamine B2 et 20,5 mg de vitamine B3.